Korea Pharma Applies for National Health Insurance Reimbursement Listing for Iron Deficiency Treatment 'Acrupper'
Published
Korea Pharma announced that it has applied for the National Health Insurance reimbursement listing of 'Acrupper,' an iron deficiency treatment. If the drug is listed for reimbursement, patients will be able to take it at a lower cost by receiving health insurance coverage.
The main ingredient of Acrupper is ferric maltol. Ferric maltol is a compound in which iron and maltol are stably bonded. The drug is an oral treatment taken twice a day.
According to the company, ferric maltol is designed to minimize the amount of free iron exposed within the gastrointestinal tract. Free iron refers to iron that circulates freely in the body, and the company explains that reducing it can lessen the burden on the gastrointestinal tract.
This application appears to be aimed at making it easier for iron deficiency patients to access the treatment. Going forward, whether the drug will be listed for reimbursement will be decided after review by the Health Insurance Review and Assessment Service and related institutions.
Sources: 머니투데이
More South Korea news
- Digital TVET master's program launches in South Korea
- Gyeongbuk health group donates 100 boxes of grapes to children
- US Big Tech Pursues Multi-Trillion Won Investments in South Korean Data Centers Amid Uncertainty
- KB Insurance to Hold Open Recruitment for New Employees in Second Half of 2026
- Kolmar Korea Wins CES Beauty Tech Best Innovation Award for Second Straight Year, Setting World First
- China Closes In on Korea's Core LNG Carrier Market, Expanding from Mega-Vessels to Equipment
- China's Rapid Technological Development: South Korea Must Change Its Regulations and Labor System
- Ambassador Michelle Steel: American Companies Operating in Korea Should Compete in a Fair Environment